JP2013518061A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518061A5
JP2013518061A5 JP2012550265A JP2012550265A JP2013518061A5 JP 2013518061 A5 JP2013518061 A5 JP 2013518061A5 JP 2012550265 A JP2012550265 A JP 2012550265A JP 2012550265 A JP2012550265 A JP 2012550265A JP 2013518061 A5 JP2013518061 A5 JP 2013518061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
phenylaminoethane
hydrazide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012550265A
Other languages
English (en)
Japanese (ja)
Other versions
JP5788907B2 (ja
JP2013518061A (ja
Filing date
Publication date
Priority claimed from AT0012210A external-priority patent/AT509045B1/de
Application filed filed Critical
Publication of JP2013518061A publication Critical patent/JP2013518061A/ja
Publication of JP2013518061A5 publication Critical patent/JP2013518061A5/ja
Application granted granted Critical
Publication of JP5788907B2 publication Critical patent/JP5788907B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012550265A 2010-01-29 2011-01-28 疾患の治療に使用される化合物 Expired - Fee Related JP5788907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA122/2010 2010-01-29
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen

Publications (3)

Publication Number Publication Date
JP2013518061A JP2013518061A (ja) 2013-05-20
JP2013518061A5 true JP2013518061A5 (https=) 2014-02-13
JP5788907B2 JP5788907B2 (ja) 2015-10-07

Family

ID=43707937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550265A Expired - Fee Related JP5788907B2 (ja) 2010-01-29 2011-01-28 疾患の治療に使用される化合物

Country Status (12)

Country Link
US (1) US20130065962A1 (https=)
EP (2) EP2528595B1 (https=)
JP (1) JP5788907B2 (https=)
KR (1) KR20120128644A (https=)
CN (2) CN102858329B (https=)
AT (1) AT509045B1 (https=)
AU (1) AU2011208939B2 (https=)
BR (1) BR112012018772A2 (https=)
CA (1) CA2788326A1 (https=)
MX (1) MX2012008815A (https=)
SG (1) SG182786A1 (https=)
WO (1) WO2011091461A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022923A1 (en) * 2012-08-10 2014-02-13 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
KR20170066614A (ko) * 2014-10-10 2017-06-14 프로메틱 파마 에스엠티 리미티드 당뇨병의 예방 및 치료를 위한 치환된 방향족 화합물 및 약제학적 조성물
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
KR102939715B1 (ko) * 2021-03-31 2026-03-17 셰브런 오로나이트 컴퍼니 엘엘씨 저속 사전 점화 이벤트를 완화하기 위한 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
ES2104938T3 (es) 1991-04-01 1997-10-16 Univ Duke Metodo de inhibir la fibrosis.
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
WO2000015215A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
WO2000073280A1 (en) 1999-05-28 2000-12-07 Cheil Jedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
EP1603858A2 (en) 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
US7514470B2 (en) 2004-03-03 2009-04-07 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
EA022445B1 (ru) * 2009-05-04 2016-01-29 Прометик Байосайенсиз Инк. Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения

Similar Documents

Publication Publication Date Title
JP2023002662A5 (https=)
JP2016534063A5 (https=)
JP2009514874A5 (https=)
JP2010518122A5 (https=)
JP2010077141A5 (https=)
JP2012502037A5 (https=)
JP2013542247A5 (https=)
JP2011201907A5 (https=)
JP2018507914A5 (https=)
JP2017528507A5 (https=)
JP2016534153A5 (https=)
JP2015057436A5 (https=)
JP2014505107A5 (https=)
JP2012520866A5 (https=)
JP2009102342A5 (https=)
JP2013534248A5 (https=)
JP2013507415A5 (https=)
JP2013520405A5 (https=)
JP2013518107A5 (https=)
JP2006182786A5 (https=)
JP2014500861A5 (https=)
JP2017526716A5 (https=)
JP2023504415A5 (https=)
JP2010521417A5 (https=)
JP2012255002A5 (https=)